Increased plasma amyloid β protein 1–42 levels in Down syndrome

• Published in: Neuroscience letters Vol. 241; no. 1; pp. 13 - 16
• Main Authors: Mehta, Pankaj D, Dalton, Arthur J, Mehta, Sangita P, Kim, Kwang Soo, Sersen, Eugene A, Wisniewski, Henryk M
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 23.01.1998; Elsevier
• Subjects: Adult; Aged; Aged, 80 and over; Amyloid beta-Peptides - blood; Amyloid β protein 1–40; Amyloid β protein 1–42; Biological and medical sciences; Chromosome aberrations; Down syndrome; Down Syndrome - blood; Down Syndrome - genetics; Enzyme linked immunosorbent assay; Female; Gene Dosage; Humans; Intellectual Disability - blood; Intellectual Disability - genetics; Male; Medical genetics; Medical sciences; Mentally retarded; Middle Aged; Normal controls; Peptide Fragments - blood; Plasma; Trisomy; Plasma; Amyloid β protein 1–42; Enzyme linked immunosorbent assay; Mentally retarded; Normal controls; Down syndrome; Amyloid β protein 1–40; Chromosomal aberration; Human; Trisomy; β Amyloid protein; Aneuploidy; Mental retardation; ELISA assay; Blood plasma
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/S0304-3940(97)00966-X

Amyloid β protein 1–40 (A β40) and A β42 levels were quantitated in plasma from 43 persons with Down syndrome (DS; 26–68 years of age), 43 age-matched normal controls, and 19 non-DS mentally retarded (MR) persons (26–91 years of age) by using a sandwich enzyme linked immunosorbent assay. A β40 levels were higher in DS and MR than controls, but were similar between DS and MR groups. A β42 levels were higher in DS than controls or MR persons. The ratios of A β42/A β40 were higher in DS than controls or MR persons. The findings are consistent with those seen in DS brains.